AEON Biopharma, Inc.
AEON- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001837607
In the last 90 days, AEON Biopharma, Inc. insiders filed 1 open-market purchase and 0 sales; 22 institutions reported holding it in 13F filings for Q2 2026, worth $9.22M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in AEON Biopharma, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +4 vs. Q3 2023
- Shares held
- 8.67M
- +3.60M (+71.1%) vs. Q3 2023
- Total value
- $56.8M
- +$27.5M (+94.2%) vs. Q3 2023
- New holders
- 6
- 5 more added
- Sold out
- 2
- 3 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AEON on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $9.22M |
| Q1 2026 | 24 | $2.80M |
| Q4 2025 | 22 | $1.67M |
| Q3 2025 | 21 | $1.10M |
| Q2 2025 | 18 | $585.7K |
| Q1 2025 | 16 | $884.8K |
| Q4 2024 | 37 | $4.80M |
| Q3 2024 | 30 | $10.1M |
| Q2 2024 | 25 | $8.73M |
| Q1 2024 | 27 | $103.5M |
| Q4 2023 | 20 | $56.8M |
| Q3 2023 | 16 | $29.3M |
| Q2 2023 | 17 | $12.0M |
| Q1 2023 | 21 | $19.6M |
| Q4 2022 | 86 | $248.3M |
| Q3 2022 | 81 | $226.5M |
| Q2 2022 | 73 | $213.1M |
| Q1 2022 | 71 | $202.3M |
| Q4 2021 | 73 | $192.0M |
| Q3 2021 | 59 | $171.8M |
| Q2 2021 | 47 | $126.0M |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding AEON Biopharma, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DuPont Capital Management Corp | 3 | $22 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 99 | $713 | 0.00% | −348−77.9% | Reduced |
| Wells Fargo & Company | 137 | $986 | 0.00% | +7+5.4% | Added |
| UBS Group AG | 649 | $4.67K | 0.00% | +649 | New |
| GHP Investment Advisors, Inc. | 1,095 | $7.88K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,800 | $13.0K | 0.00% | +1,800 | New |
| Qube Research & Technologies Ltd | 3,924 | $28.3K | 0.00% | +3,924 | New |
| JPMorgan Chase & Co | 6,889 | $49.6K | 0.00% | +6,889 | New |
| State Street Corp | 10,050 | $72.4K | 0.00% | +10,050 | New |
| Goldman Sachs Group Inc | 18,543 | $133.5K | 0.00% | −5,765−23.7% | Reduced |
| Bank of America Corp | 23,353 | $168.1K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 49,819 | $358.7K | 0.00% | +17,341+53.4% | Added |
| Boothbay Fund Management, LLC | 55,062 | $396.4K | 0.01% | 00.0% | Unchanged |
| Formidable Asset Management, LLC | 58,193 | $419.0K | 0.09% | −6,118−9.5% | Reduced |
| Geode Capital Management, LLC | 172,246 | $1.24M | 0.00% | +900+0.5% | Added |
| Vanguard Group Inc | 209,785 | $1.51M | 0.00% | +16,091+8.3% | Added |
| BlackRock Inc. | 247,088 | $1.78M | 0.00% | +5,522+2.3% | Added |
| Ikarian Capital, LLC | 257,977 | $1.86M | 0.51% | 00.0% | Unchanged |
| Atalaya Capital Management LP | 3,675,000 | $22.6M | 32.55% | 00.0% | Unchanged |
| Polar Asset Management Partners Inc. | 3,875,000 | $26.2M | 0.71% | +3,875,000 | New |
| Rivernorth Capital Management, LLC | 0 | $0 | 0.00% | −314,426−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −10,612−100.0% | Sold out |